Monday, 31 August 2026European Markets
ExploreSearch
ViaNews EU

Enterprise Technology

2 articles

Snowflake BUILD London Showcases Cloud AI Battle for European Enterprise Customers

Snowflake BUILD London Showcases Cloud AI Battle for European Enterprise Customers

Snowflake's BUILD London 2026 conference demonstrated AI capabilities including Cortex functions and agent evaluations as cloud providers compete for European enterprise adoption. HSBC and Lloyds represent financial institutions migrating to cloud AI platforms. Analysts signal continued AI infrastructure investment with Wolfe Research naming Nvidia top pick and Morgan Stanley raising ASML targets 40%.

ViaNews Editorial Team (Europe)•
Snowflake Launches AI Development Suite in London as European Financial Services Accelerate Cloud AI Adoption

Snowflake Launches AI Development Suite in London as European Financial Services Accelerate Cloud AI Adoption

Snowflake unveiled production-ready AI tools at BUILD London 2026, including Cortex AI Functions, Notebooks GA, and Agent Evaluations, targeting European enterprises in regulated sectors. The launch mirrors aggressive AI platform expansions by AWS Bedrock, Google Cloud Vertex AI, and Azure AI as cloud vendors compete for enterprise AI workloads. European financial institutions including HSBC, BNP Paribas, and Citigroup are early adopters of embedded agentic capabilities.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com